Gossamer Bio, Inc. (GOSS)

0.7075 -0.0025 (-0.35%) 收市：04:00PM EDT

Gossamer Bio, Inc.

3013 Science Park Road
Suite 200
San Diego, CA 92121
United States
858 684 1300
https://www.gossamerbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 135

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Faheem Hasnain	Co-Founder, CEO, President & Chairman	910.26k	無	1958
Mr. Bryan Giraudo	COO & CFO	708.09k	無	1975
Mr. Robert P. Smith	Chief Commercial Officer	135.79k	無	1969
Mr. Christian Waage	Executive Vice President of Technical Operations & Administration	583.16k	無	1967
Mr. Jeff Boerneke	General Counsel & Secretary	無	無	無
Ms. Deanna Weber	Senior Vice President of Human Resources	無	無	無
Dr. Richard Aranda M.D.	Chief Medical Officer	625.24k	無	1961
Mr. Mario Orlando	Senior Vice President of Commercial New Product Planning	無	無	無
Ms. Caryn L. Peterson	Executive Vice President of Regulatory Affairs	無	無	1959
Mr. Matt Cravets	Senior Vice President of Biometrics	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

公司管治

截至 2024年4月29日 止，Gossamer Bio, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：7；董事會：7；股東權利：8；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。